ST. LOUIS, May 29, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announces the successful treatment of the first heart rhythm patients by Penn Presbyterian Medical Center (PPMC) utilizing the advanced Genesis Robotic Magnetic Navigation System. PPMC, part of the University of Pennsylvania Health System, renowned for advanced clinical research, innovation, and compassionate patient care, stands at the forefront as the ...

Stereotaxis (STXS) a pioneer in surgical robotics for minimally invasive endovascular intervention, recently announced its successful recertification under the European Union's Medical Device Regulation (MDR). This significant milestone, which covers all Stereotaxis devices currently available in Europe, marks a crucial advancement in the company's pursuit of excellence in the surgical robotics market. The News in Detail The MDR (Regulation (EU) 2017/745) replaces the previous European Medical Device Direct ...

Stereotaxis (STXS) recently announced that the first robotic cardiac heart program in Southern Italy had been developed at Hospital Santa Maria della Pietà, Nola. With the help of this cutting-edge technology, patients with heart rhythm abnormalities can now be effectively treated with robotic ablation treatments. Hospital Santa Maria della Pietà is the first hospital in Italy to use the latest generation of Genesis Robotic Magnetic Navigation (RMN) system. Price Performance For the past six months, STXS's ...

ST. LOUIS, May 24, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has received CE Mark recertification under the European Union's new Medical Device Regulation (MDR) regulatory framework. The recertification under MDR covers all Stereotaxis devices currently available in Europe. MDR (Regulation (EU) 2017/745) replaces the former European Medical Device Directive, which had governed ...

MDR (Regulation (EU) 2017/745) replaces the former European Medical Device Directive, which had governed the approval and marketing of medical devices in the EU. The new regulation includes more stringent standards and requirements across quality, clinical and post-market surveillance areas. It is intended to create a robust regulatory framework for improved clinical safety and market access for medical devices. Stereotaxis has now received its updated EU Quality Management System Certificate. This certific ...

Stereotaxis Reports Solid Results We must contextualize Stereotaxis' (NYSE:STXS) reported results until their new products get approved. The company will have limited sales growth and a modest cash burn in the meantime. This doesn't mean we shouldn't analyze the current business. It just shouldn't be where the majority of our focus lies. I have fairly low expectations for the existing business, but very high expectations for the medium term (next ~2 years). With that in mind, let's briefly look at the Q1 re ...

ST. LOUIS, May 22, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announced that Hospital Santa Maria della Pietà, in Nola in the Metropolitan City of Naples, has established the first robotic cardiac heart program in Southern Italy. Patients suffering from heart rhythm disorders are now being successfully treated with robotic ablation procedures using this advanced technology, and Hospital Santa Maria della Pietà is ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-36159 STEREOTAXIS, INC. DELAWARE 94-3120386 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Iden ...

Stereotaxis, Inc. (NYSE:STXS) Q1 2024 Earnings Conference Call May 13, 2024 4:30 PM ET Company Participants David Fischel - Chairman and Chief Executive Officer Kimberly Peery - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Jason Wittes - ROTH MKM Adam Maeder - Piper Sandler Joshua Jennings - TD Cowen Operator Good afternoon. Thank you for joining us for Stereotaxis' First Quarter 2024 Earnings Conference Call. Certain statements during the conference call ...

Exhibit 99.1 "Stereotaxis is driving continued commercial, technological, and strategic progress," said David Fischel, Chairman and CEO. "We are pleased to report revenue growth in the first quarter and an increase in system backlog with two Genesis systems orders since our last call. Our innovation strategy remains key to driving substantial commercial success, and we are making robust progress on multiple fronts in line with previous timelines. The acquisition of APT, as detailed in a separate press relea ...